Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × Disease × Clear all

Phase

Phase 2 8 Phase NA 4 Phase 3 4 Phase 1/2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 17 Prostatic Neoplasms 14 Breast Neoplasms 9 Leukemia, Myeloid, Acute 8 Recurrence 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neoplasm Metastasis 6 Ovarian Neoplasms 5 Myelodysplastic Syndromes 5 Multiple Myeloma 5 Colorectal Neoplasms 5 Melanoma 4 Lymphoma, Non-Hodgkin 4 Fatigue 4 Vomiting 3 Stomach Neoplasms 3 Prostatic Neoplasms, Castration-Resistant 3 Pain 3 Nausea 3 Mesothelioma 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma 3 Liposarcoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Depression 3 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02981368 2021-08-09

OSPREY

Progenics Pharmaceuticals, Inc.

Phase 2/3 Completed

385 enrolled 20 charts

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡